Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

Torrid times at Gilead lead to calls for a major M&A deal

HIV portfolio sales down almost 10% to $7.5bn despite strong $533m start for Epclusa

Immunisation politicised

The case of Human Papilloma Virus

- PMLiVE

Enterprise Therapeutics appoints CEO

Dr John Ford will lead the UK drug discovery company

- PMLiVE

NICE set to reject Merck’s Erbitux for head and neck cancer

Draft guidance rules the treatment does not provide value for money

- PMLiVE

‘Hard’ Brexit could mean a longer wait for new drugs, says report

Warns of deprioritised status if negotiators fail to secure access to the single market

- PMLiVE

Pfizer dropping bococizumab casts shadow over PCSK9 class

US payer resistance and diminishing efficacy prompt decision on would-be blockbuster

- PMLiVE

Orphan drugs: Leading the way in patient-centricity

What lessons about optimal patient engagement can big pharma learn from those operating in rare disease?

- PMLiVE

Clark Health Communications expands senior team

Deborah Corcoran, James Todman and Hannah Walsh join

- PMLiVE

Merck licenses University of Edinburgh research tool

Gains access to novel disease progression technology

- PMLiVE

Teva expands eHealth alliance with IBM

Taps Watson Health Cloud for drug development and disease management work

- PMLiVE

Takeda launches drug discovery biotech

Hopes Bridge Medicines will streamline the development process

- PMLiVE

Valeant’s ex-CEO and CFO ‘could face criminal charges’

Sources suggest probe may relate to the company’s former relationship with Philidor Rx Services

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links